Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Feb 2, 2021 (6 years ago)

Enoxaparin Sodium Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Enoxaparin Sodium Injection, USP 120 mg/ 0.8 mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 0.8 mL Single Dose Syringes Rx Only,Manufactured by: Gland Pharma Ltd. Hyderabad, India Manufactured for: Apotex Corp. Weston, FL 33326 NDC 60505-0796-4 UPC 360505079543 (carton) NDC 60505-0796-0 UPC (01)10360505079602 (label)

Affected NDCs 60505-0796-00 60505-0796-04

Compare with the code on your package — it is the most precise check available.

Drug: Enoxaparin

Recalling firm
Apotex Corp.
NDC code
60505-0796-4
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0262-2021 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Enoxaparin recalls

See all
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Enoxaparin Sodium Injection

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0179-2024
Class I · High risk

Enoxaparin Sodium Injection

Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)

Ongoing Labeling / mix-up Apotex Corp. NDC 60505-0795-4 D-0261-2021

Other recalls by Apotex Corp.

All 2021 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026